Login to Your Account



Genentech Earnings Tops Again, But Tarceva Concern Has Impact

By Randall Osborne


Friday, April 11, 2003
Genentech Inc. reported first-quarter earnings higher than Wall Street expectations - a 59 percent hike in non-GAAP (formerly pro forma) earnings per share - but the company told investors of potential safety issues in one Phase III study with the anticancer drug Tarceva, news that put the biggest dent in shares of Tarceva partner OSI Pharmaceuticals Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription